Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
Public ClinicalTrials.gov record NCT06099184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME)
Study identification
- NCT ID
- NCT06099184
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Interventions
- Aflibercept 2Mg/0.05Ml Inj,Oph Drug
- EYP-1901 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 14, 2024
- Primary completion
- Oct 23, 2024
- Completion
- Oct 23, 2024
- Last update posted
- Mar 3, 2025
2024
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| EyePoint Investigative Site | Phoenix | Arizona | 85020 | — |
| EyePoint Investigative Site | Lemont | Illinois | 60439 | — |
| EyePoint Investigative Site | Hagerstown | Maryland | 21740 | — |
| EyePoint Investigative Site | Reno | Nevada | 89502 | — |
| EyePoint Investigative Site | Erie | Pennsylvania | 16507 | — |
| EyePoint Investigative Site | Lynchburg | Virginia | 24502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06099184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2025 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06099184 live on ClinicalTrials.gov.